Treatment of lung cancer--state of the art in 2000

Y. Nakanishi, K. Inoue, N. Hara

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Small-cell lung cancer (SCLC) is, in general, sensitive to anti-cancer chemotherapy and radiotherapy. Standard therapies for extensive SCLC are combination chemotherapies with cyclophosphamide, adriamycin and vincristine (CAV), with cisplatin and etoposide (PE), as well as an alternating CAV/PE program. On the other hand, the standard therapy for limited SCLC is chemoradiotherapy, especially PE and concurrent accelerated hyperfractionated radiotherapy. Based on the therapy, the current state of treatment of small cell lung disease is a median survival time of 10 months and a 3-year survival in 10% of patients with extensive disease, and a median survival time of 30 months and a 3-year survival in 30% of patients with limited disease. Promising trials under investigation including those for dose-intensive chemotherapy, multimodality treatment and combination chemotherapy adopting new drugs are introduced. The standard therapy for inoperable stage III non-small cell lung cancer is a multimodality therapy employing chemotherapy and radiotherapy. However, neither the timing of the radiotherapy nor the optimal combination of anti-cancer agents has yet been established. Nowadays, the combination of cisplatin-based chemotherapy and radiotherapy is expected to bring a median survival time of 15 months and a 3-year survival in 25% of patients. For stage IV non-small cell lung cancer, chemotherapy prolongs survival time by a modest but statistically significant amount of time. For the treatment of inoperable lung cancer, the survival benefit from the use of newly developed drugs with or without platinum is under investigation.

Original languageEnglish
Pages (from-to)1247-1252
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume27
Issue number8
Publication statusPublished - Jul 2000

Fingerprint

Lung Neoplasms
Survival
Radiotherapy
Small Cell Lung Carcinoma
Drug Therapy
Vincristine
Therapeutics
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Doxorubicin
Cyclophosphamide
Cisplatin
Chemoradiotherapy
Etoposide
Platinum
Pharmaceutical Preparations
Lung Diseases
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakanishi, Y., Inoue, K., & Hara, N. (2000). Treatment of lung cancer--state of the art in 2000. Gan to kagaku ryoho. Cancer & chemotherapy, 27(8), 1247-1252.

Treatment of lung cancer--state of the art in 2000. / Nakanishi, Y.; Inoue, K.; Hara, N.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 27, No. 8, 07.2000, p. 1247-1252.

Research output: Contribution to journalReview article

Nakanishi, Y, Inoue, K & Hara, N 2000, 'Treatment of lung cancer--state of the art in 2000', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 27, no. 8, pp. 1247-1252.
Nakanishi, Y. ; Inoue, K. ; Hara, N. / Treatment of lung cancer--state of the art in 2000. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2000 ; Vol. 27, No. 8. pp. 1247-1252.
@article{f4d9dd29703a437aa2f86b2437a51435,
title = "Treatment of lung cancer--state of the art in 2000",
abstract = "Small-cell lung cancer (SCLC) is, in general, sensitive to anti-cancer chemotherapy and radiotherapy. Standard therapies for extensive SCLC are combination chemotherapies with cyclophosphamide, adriamycin and vincristine (CAV), with cisplatin and etoposide (PE), as well as an alternating CAV/PE program. On the other hand, the standard therapy for limited SCLC is chemoradiotherapy, especially PE and concurrent accelerated hyperfractionated radiotherapy. Based on the therapy, the current state of treatment of small cell lung disease is a median survival time of 10 months and a 3-year survival in 10{\%} of patients with extensive disease, and a median survival time of 30 months and a 3-year survival in 30{\%} of patients with limited disease. Promising trials under investigation including those for dose-intensive chemotherapy, multimodality treatment and combination chemotherapy adopting new drugs are introduced. The standard therapy for inoperable stage III non-small cell lung cancer is a multimodality therapy employing chemotherapy and radiotherapy. However, neither the timing of the radiotherapy nor the optimal combination of anti-cancer agents has yet been established. Nowadays, the combination of cisplatin-based chemotherapy and radiotherapy is expected to bring a median survival time of 15 months and a 3-year survival in 25{\%} of patients. For stage IV non-small cell lung cancer, chemotherapy prolongs survival time by a modest but statistically significant amount of time. For the treatment of inoperable lung cancer, the survival benefit from the use of newly developed drugs with or without platinum is under investigation.",
author = "Y. Nakanishi and K. Inoue and N. Hara",
year = "2000",
month = "7",
language = "English",
volume = "27",
pages = "1247--1252",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "8",

}

TY - JOUR

T1 - Treatment of lung cancer--state of the art in 2000

AU - Nakanishi, Y.

AU - Inoue, K.

AU - Hara, N.

PY - 2000/7

Y1 - 2000/7

N2 - Small-cell lung cancer (SCLC) is, in general, sensitive to anti-cancer chemotherapy and radiotherapy. Standard therapies for extensive SCLC are combination chemotherapies with cyclophosphamide, adriamycin and vincristine (CAV), with cisplatin and etoposide (PE), as well as an alternating CAV/PE program. On the other hand, the standard therapy for limited SCLC is chemoradiotherapy, especially PE and concurrent accelerated hyperfractionated radiotherapy. Based on the therapy, the current state of treatment of small cell lung disease is a median survival time of 10 months and a 3-year survival in 10% of patients with extensive disease, and a median survival time of 30 months and a 3-year survival in 30% of patients with limited disease. Promising trials under investigation including those for dose-intensive chemotherapy, multimodality treatment and combination chemotherapy adopting new drugs are introduced. The standard therapy for inoperable stage III non-small cell lung cancer is a multimodality therapy employing chemotherapy and radiotherapy. However, neither the timing of the radiotherapy nor the optimal combination of anti-cancer agents has yet been established. Nowadays, the combination of cisplatin-based chemotherapy and radiotherapy is expected to bring a median survival time of 15 months and a 3-year survival in 25% of patients. For stage IV non-small cell lung cancer, chemotherapy prolongs survival time by a modest but statistically significant amount of time. For the treatment of inoperable lung cancer, the survival benefit from the use of newly developed drugs with or without platinum is under investigation.

AB - Small-cell lung cancer (SCLC) is, in general, sensitive to anti-cancer chemotherapy and radiotherapy. Standard therapies for extensive SCLC are combination chemotherapies with cyclophosphamide, adriamycin and vincristine (CAV), with cisplatin and etoposide (PE), as well as an alternating CAV/PE program. On the other hand, the standard therapy for limited SCLC is chemoradiotherapy, especially PE and concurrent accelerated hyperfractionated radiotherapy. Based on the therapy, the current state of treatment of small cell lung disease is a median survival time of 10 months and a 3-year survival in 10% of patients with extensive disease, and a median survival time of 30 months and a 3-year survival in 30% of patients with limited disease. Promising trials under investigation including those for dose-intensive chemotherapy, multimodality treatment and combination chemotherapy adopting new drugs are introduced. The standard therapy for inoperable stage III non-small cell lung cancer is a multimodality therapy employing chemotherapy and radiotherapy. However, neither the timing of the radiotherapy nor the optimal combination of anti-cancer agents has yet been established. Nowadays, the combination of cisplatin-based chemotherapy and radiotherapy is expected to bring a median survival time of 15 months and a 3-year survival in 25% of patients. For stage IV non-small cell lung cancer, chemotherapy prolongs survival time by a modest but statistically significant amount of time. For the treatment of inoperable lung cancer, the survival benefit from the use of newly developed drugs with or without platinum is under investigation.

UR - http://www.scopus.com/inward/record.url?scp=0034222358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034222358&partnerID=8YFLogxK

M3 - Review article

C2 - 10945023

AN - SCOPUS:0034222358

VL - 27

SP - 1247

EP - 1252

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 8

ER -